Advertisement News Archives - Page 1751 of 5230 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

July 29, 2026

FDA grants fast track designation for HAYA Therapeutics’ HTX-001

HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

FDA grants fast track designation for HAYA Therapeutics’ HTX-001